乙肝病毒携带者及慢性乙肝抗病毒治疗及疗效及非特异性免疫激活药.docVIP

乙肝病毒携带者及慢性乙肝抗病毒治疗及疗效及非特异性免疫激活药 　 作者：韩祖良　孙渝生　李欣其 　　论文关键词；乙肝病毒携带者　慢性乙型肝炎　拉米夫定　　草分枝杆菌F.U.36　药物同步联合应用　野生型乙肝病毒突变成为前-C区变异株 　　论文摘要：目的 以药物单独应用和药物联合应用的治疗方式，探索乙肝病毒携带者和慢性乙型肝炎患者获取HBV-DNA转阴的疗效与非特异性免疫激活药物选择应用的关系；方法 将255例HBeAg阳性和阴性的乙肝病毒携带者和慢性乙型肝炎患者随机分成2组；观察拉米夫定和草分枝杆菌F.U.36与中药（A组）和拉米夫定与中药（B组），对HBV-DNA的疗效作用，以及疗效的安全性问题等，疗程3个月，追踪观察9个月；结果1）B组对慢性乙型肝炎HBV-DNA的转阴率，显著地高于对乙肝病毒携带者的疗效，P＜0,01；2）A组对慢性乙性肝炎HBV-DNA的转阴率，显著地高于B组的转阴率，P＜0,01；3）A组对HBeAg阴性的乙肝病毒携带者HBV-DNA的转阴率，显著地高于B组和HBeAg阳性的乙肝病毒携带者的转阴率，P＜0,01等，治疗过程未见有任何不良的反应；结论 非特异性免疫激活药物的选择应用与HBV-DNA获取转阴的疗效有关，HBV-DNA获取转阴的疗效与谷丙转氨酶获得复常的结果有关，进而获得了构成谷丙转氨酶异常的原因与非特异性免疫应答状态发生变化的结果有关，抗HBV治疗获取HBV-DNA转阴的疗效与非特异性免疫应答能力获得提高或改善的结果有关等。 Abstract：Purpose asymptomatic carriers, chronic hepatitis B HBV-DNA to obtain the effect of negative results, with the drug alone or the relationship between the drug combination;Methods 255 cases will be positive and HBeAg-negative hepatitis B virus carriers and chronic hepatitis B were randomly divided into 2 groups; observation of lamivudine and Mycobacterium phlei FU36 and traditional Chinese medicine (A group) and lamivudine with traditional Chinese medicine (B group ), on the efficacy of HBV-DNA, as well as the efficacy of the security issues and so on, treatment 3 months, 9 months follow-up; Results 1）B group patients with chronic hepatitis B HBV-DNA to obtain the negative rate, significantly higher than that of the efficacy of asymptomatic carriers, P lt;0,01 2) A group patients with chronic hepatitis B HBV-DNA to obtain the negative rate, significantly higher than that of the negative rate of B group, P lt;0,01;3) A group of HBeAg-negative asymptomatic carriers of HBV-DNA negative rate，significantly higher than the B group and HBeAg-positive asymptomatic carriers negative rate, P lt;0,01 etc。The whole course of treatment not known to have any adverse reaction; Conclusions Non-specific immune activation of the choice of drug applications, with HBV-DNA to obtain the effect of negative results, HBV-DNA to obtain the effect of nega